Lytton Laurence is Buying Catalyst Biosciences (NASDAQ:CBIO) Shares

0
463

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catalyst Biosciences Inc. (NASDAQ:CBIO) reported that Lytton Laurence W has picked up 220,500 of common stock as of 2017-04-13.

The acquisition brings the aggregate amount owned by Lytton Laurence W to a total of 220,500 representing a 8.1% stake in the company.

For those not familiar with the company, Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

A glance at Catalyst Biosciences Inc. (NASDAQ:CBIO)’s key stats reveals a current market capitalization of 5.00 Million based on 1.00 Million shares outstanding and a price at last close of $5.41 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-12-17, Usman picked up 4,000 at a purchase price of $2.00. This brings their total holding to 78,375 as of the date of the filing.

On the sell side, the most recent transaction saw Barris unload 1,000 shares at a sale price of $5.13. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Catalyst Biosciences Inc. (NASDAQ:CBIO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.